Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Revance Therapeutics (RVNC) Gets a Hold From Mizuho Securities
Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Conmed (CNMD) and Revance Therapeutics (RVNC)
Revance Therapeutics, Crown Labs Tender Offer Extended Until Oct. 18
Express News | Revance Therapeutics: Extends Tender Offer Commencement Date to Oct 18
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround
Top Premarket Decliners
Express News | Revance Therapeutics-Co’s Ongoing Discussions With Teoxane and Buyer Parties Could Result in Delays to Consummation of Offer
Express News | Revance Therapeutics- on Aug 16, Co Got Notice to Remedy Alleged Material Breaches, Under Co’s Exclusive Distribution Deal With Teoxane SA
Deals This Week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and More
Guggenheim Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $6.66
Crown Labs Tender Offer for Revance Delayed, Expect Deal to Be Completed - Analyst
Revance Therapeutics Falls as Crown Labs Didn't Start Tender Offer by Deadline
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Revance Therapeutics Cut to Equal-Weight From Overweight by Barclays
Revance Therapeutics Analyst Ratings
Barclays Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $7
Revance has been acquired for 0.924 billion U.S. dollars! Fosun Pharma (600196.SH) holds exclusive commercialization rights for its star botulinum toxin product in China.
Revance is acquired for $0.924 billion.
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Has Obtained a Fair Price for Its Public Shareholders
H.C. Wainwright Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $6.6